多西他赛联合卡培他滨新辅助化疗方案治疗局部晚期乳腺癌的临床观察(英文)

多西他赛联合卡培他滨新辅助化疗方案治疗局部晚期乳腺癌的
临床观察(英文)
Miao Zhang;Jianing Qiu;Shuxian Qu;Yaling Han;Zhaozhe Liu;Xiaodong Xie
【期刊名称】《中德临床肿瘤学杂志：英文版》
【年(卷),期】2014(0)11
【摘要】Objective: The recent clinical curative effect and adverse events of docetaxel and capecitabine(DX) of neoadjuvant chemotherapy in patients with locally advanced breast cancer was discussed. Methods: The data of 72 cases of neoadjuvant chemotherapy(DX) in locally advanced breast cancer after 4 cycles were retrospectively analyzed. Docetaxel 75 mg/m2 by infusion 1 h on d1, capecitabine 2000 mg/m2 by oral for twice daily on d1–14, 21 days was a cycle. Results: All 72 patients were assessed for efficacy and adverse events. The total effective rate was 80.5%(58/72), including pathological complete response(p CR) was 7(9.7%), clinical complete remission(c CR) was 15(20.8%), clinical partial response(PR) was 43(59.7%), stable disease(SD) was 8(11.1%) and progressive disease(PD) was 6(8.3%). The main adverse events were gastrointestinal reactions and bone marrow suppression. The 3 to 4 degrees of adverse reactions including granulocytopenia in 7 patients(20.6%), hand-foot syndrome in 6 patients(15.2%). Conclusion: The DX regimen provide a favorable efficacy and safety profile in patients with locally advanced breast cancer for neoadjuvant chemotherapy.
【总页数】3页(P515-517)
【关键词】临床观察;乳腺癌;晚期;化疗;临床疗效;不良反应;有效率;PCR
【作者】Miao Zhang;Jianing Qiu;Shuxian Qu;Yaling Han;Zhaozhe
Liu;Xiaodong Xie
【作者单位】Graduate School, Dalian Medical University;Oncology Department, General Hospital of Shenyang Military Region
【正文语种】中文
【中图分类】S858.292;S896.3
【相关文献】
1.卡培他滨联合多西他赛新辅助化疗治疗局部晚期乳腺癌疗效及安全性分析 [J], 谢金龙
2.晚期乳腺癌应用多西他赛联合卡培他滨行新辅助化疗的临床观察 [J], 刘存贞;孙强;马君花;刘德兰
3.多西他赛与表柔比星联合用于局部晚期乳腺癌新辅助化疗的临床疗效观察 [J], 吴建亮;徐怡;吴立新
4.多西他赛联合卡培他滨方案在新辅助化疗三阴乳腺癌与非三阴乳腺癌中的近期疗效观察 [J], 张淼;宋敏;屈淑贤;章国晶;郭放;韩雅玲;谢晓冬
5.多西他赛联合卡培他滨方案在新辅助化疗三阴乳腺癌与非三阴乳腺癌中的近期疗效观察 [J], 张淼;宋敏;屈淑贤;章国晶;郭放;韩雅玲;谢晓冬;
因版权原因，仅展示原文概要，查看原文内容请购买。